Therapy Detail

Therapy Name Vistusertib
Therapy Description

Vistusertib (AZD2014) inhibits the activity of mTOR, which may result in tumor growth inhibition (PMID: 23375793).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Vistusertib AZD2014 mTOR Inhibitor 48 Vistusertib (AZD2014) inhibits the activity of mTOR, which may result in tumor growth inhibition (PMID: 23375793).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown colorectal cancer not applicable Vistusertib Preclinical - Cell line xenograft Actionable In a preclinical study, Vistusertib (AZD2014) induced apoptosis and decreased viability of colorectal cancer cell lines in culture, and inhibited tumor growth in colorectal cancer cell line xenograft models (PMID: 24309100). 24309100
PDGFRA act mut pancreatic cancer predicted - sensitive Vistusertib Phase I Actionable In a Phase I trial, Vistusertib (AZD2014) demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including a patient with pancreatic cancer harboring a PDGFRA activating mutation (PMID: 25805799). 25805799
ERBB2 act mut estrogen-receptor positive breast cancer predicted - sensitive Vistusertib Phase I Actionable In a Phase I trial, Vistusertib (AZD2014) demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including a patient with ER-positive breast cancer harboring an ERBB2 activating mutation (PMID: 25805799). 25805799
Clinical Trial Phase Therapies Title Recruitment Status
NCT02619864 Phase Ib/II Vistusertib mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme Active, not recruiting
NCT03071874 Phase II Vistusertib Phase II Study Of Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas Recruiting
NCT02208375 Phase Ib/II Olaparib Capivasertib Vistusertib mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Cancer Active, not recruiting
NCT02403895 Phase II Vistusertib Paclitaxel AZD2014 and Weekly Paclitaxel in Squamous NSCLC Terminated
NCT02599714 Phase Ib/II Fulvestrant + Palbociclib Vistusertib Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer (PASTOR) Active, not recruiting
NCT02831257 Phase II Vistusertib AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas Active, not recruiting